361 results on '"Liam, Chong-Kin"'
Search Results
2. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
3. Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers
4. COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV1 – a post-hoc analysis of pooled data
5. Lung Cancer Screening in Asia: An Expert Consensus Report
6. Three-dimensional topological radiogenomics of epidermal growth factor receptor Del19 and L858R mutation subtypes on computed tomography images of lung cancer patients
7. Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations
8. Clinical characteristics, cytokine profiles and plasma IgE in adults with asthma
9. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
10. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
11. Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?
12. 30-Day Readmission Rate of Patients with COPD and Its Associated Factors: A Retrospective Cohort Study from a Tertiary Care Hospital
13. Tissue coagulum clot cellblock from EBUS-TBNA for the diagnosis of necrotic lung and mediastinal lesions.
14. Symptomatic prolonged viral shedding in long COVID - Our experience with remdesivir
15. Clinical phenotypes and heath-related quality of life of COPD patients in a rural setting in Malaysia – a cross-sectional study
16. Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
17. Supplementary Table S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
18. Supplementary PLS from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
19. Data from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
20. 30-Day Readmission Rate of Patients with COPD and Its Associated Factors: A Retrospective Cohort Study from a Tertiary Care Hospital
21. Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
22. Additional file 1 of COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV1 – a post-hoc analysis of pooled data
23. Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers
24. Role of routine post‐operative laryngeal endoscopic assessment after lung cancer surgery
25. Pathological complete response in an advance stage IIIB non‐small cell lung cancer secondary to neoadjuvant osimertinib targeted therapy: A case report and review of literature.
26. Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review
27. Metastatic pulmonary calcification mimicking pulmonary tuberculosis: A case report
28. Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First-line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure
29. Abstract CT538: Tepotinib + gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT
30. Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia
31. Programmed death‐ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non‐small‐cell lung cancer in a resource‐limited country
32. Exacerbation Frequency, COPD Symptoms, and Health-Related Quality of Life of COPD Patients According to Post-Bronchodilator FEV1 – A Post-hoc Analysis of Pooled Data from Two Cross-Sectional Studies
33. Three-Dimensional Topological Radiogenomics of Epidermal Growth Factor Receptor Del19 and L858R Mutation Subtypes on Computed Tomography Images of Lung Cancer Patients
34. Tuberculin Skin Testing Among Healthcare Workers in the University of Malaya Medical Centre, Kuala Lumpur, Malaysia
35. Clinical phenotypes of COPD and health-related quality of life: a cross-sectional study
36. Lung cancer staging now and in the future
37. Management of Asthma Exacerbations in Southeast Asian Tertiary Care
38. EGFR Mutations in Asian Patients with Advanced Lung Adenocarcinoma
39. EGFR Mutation Detection by Polymerase Chain Reaction-Direct Sequencing and Allele-Specific Real-Time PCR
40. Mycobacterium Brisbanense Species Nova Isolated From a Patient With Chronic Cavitary Lung Infection
41. Lung Adenocarcinoma with Ipsilateral Pleural and Breast Metastases
42. Management of Asthma Exacerbations in Southeast Asian Tertiary Care
43. EGFR Mutation Testing for Squamous Cell Lung Carcinoma
44. Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
45. Association between anaemia, iron deficiency anaemia, neglected parasitic infections and socioeconomic factors in rural children of West Malaysia.
46. Robust radiogenomics approach to the identification of EGFR mutations among patients with NSCLC from three different countries using topologically invariant Betti numbers
47. Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma in Malaysian Patients
48. Changes in the distribution of lung cancer cell types and patient demography in a developing multiracial Asian country: Experience of a university teaching hospital
49. Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib
50. The Effect of 20-Minute Mindful Breathing on the Rapid Reduction of Dyspnea at Rest in Patients With Lung Diseases: A Randomized Controlled Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.